Chronic Fatigue Syndrome Epidemiology

The lack of a standardized definition for Chronic Fatigue Syndrome (CFS) means its prevalence is difficult to estimate.

Overall, evidence suggests a prevalence of about 0.25% to 0.40% which represents about 40 people in every 10,000 visiting a general practice. Epidemiological data for the UK is lacking but estimates based on data from other countries suggest there may be around 4000 cases of CFS per million people.

The Centres for Disease Control and Prevention (CDC) states that individuals of any age, ethnicity or gender can develop CFS but the condition is more common in men than women, in people aged 40 to 60 years and in adults as opposed to children or adolescents. People with a family member who has had the condition are also more likely to develop CFS. There is no evidence to support the theory that CFS is contagious.

The CDC estimates that over 1 million Americans have this condition and nearly 80% of these individuals are undiagnosed. According to the National Health Service, around 250,000 people in the UK have CFS.

Although people of any ethnicity or race may be affected by CFS, those from low income societies are more likely to be affected. A meta-analysis carried out in 2009 demonstrated that African Americans and Native Americans are significantly more likely to develop CFS than White Americans.

Another challenge in identifying and diagnosing cases of CFS is the presence of co-morbidity that shares symptoms with CFS. Examples include fibromyalgia, temporomandibular joint disorder, irritable bowel syndrome, interstitial cystitis, migraine, thyroid disorder, Raynaud’s phenomenon and depression.

Children and adolescents who develop the condition may find symptoms improve with age but adults often do not return to being as healthy as they were before the illness, which may also recur several years after remission. There is a high risk of progressive end-organ damage that may lead to death or even suicide.

Further Reading

Last Updated: Jul 7, 2023

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2023, July 07). Chronic Fatigue Syndrome Epidemiology. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/health/Chronic-Fatigue-Syndrome-Epidemiology.aspx.

  • MLA

    Mandal, Ananya. "Chronic Fatigue Syndrome Epidemiology". News-Medical. 31 October 2024. <https://www.news-medical.net/health/Chronic-Fatigue-Syndrome-Epidemiology.aspx>.

  • Chicago

    Mandal, Ananya. "Chronic Fatigue Syndrome Epidemiology". News-Medical. https://www.news-medical.net/health/Chronic-Fatigue-Syndrome-Epidemiology.aspx. (accessed October 31, 2024).

  • Harvard

    Mandal, Ananya. 2023. Chronic Fatigue Syndrome Epidemiology. News-Medical, viewed 31 October 2024, https://www.news-medical.net/health/Chronic-Fatigue-Syndrome-Epidemiology.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Understanding long COVID: A call for better diagnosis and treatment